CCL2 and coronary artery disorder: Treating EC with PCSK9 resulted in a significant increase in ICAM-1, VCAM-1, MCP1 and IL6 mRNA expression.<h4>Conclusions</h4>In patients with CAD, plasma PCSK9 is associated with progression of Necrotic Core-PV.